John has worked for over 25 years building value in the life sciences sector. As the Founder and Managing Director of Burloch Group, John helps connect innovators, developers and financiers to create solutions for unmet medical needs.
Prior to Burloch, John worked with emerging life sciences ventures across Ontario as a Senior Advisor at MaRS. He founded and managed the highly successful MaRS Future of Medicine™ event series that showcased leading biotech innovators.
John has also served as President and COO of Aggregate Therapeutics Inc - a Canadian stem cell "mutual fund" and from 1994 to 2006 he worked for Drug Royalty Corporation Inc (now DRI Capital) where he served as Vice President, Medical & Scientific Affairs. He completed 20 investments (totaling $250 million) with excellent returns and subsequently assisted in a $300 million investment as an independent advisor.
John holds a PhD in immunology from the University of London and is a graduate of the Canadian Securities Course.
Industry Expertise (3)
Areas of Expertise (4)
Vice President, Medical and Scientific Affairs, Drug Royalty Corporation (professional)
President & COO, Aggregate Therapeutics (professional)
Senior Advisor, Life Sciences & Healthcare, MaRS (professional)
University of London: PhD, Immunology 1991
University of Glasgow: B.Sc. (Hons), Immunology 1986
Canadian Securities Institute: Canadian Securities Certificate, Investment 1994
Event Appearances (3)
Stem cell commercialization – the Canadian experience
Progress to Therapy 2012 Glasgow, Scotland
Commercializing Life Sciences in the UK
Osgoode Hall Law School Toronto, ON
Building great companies from Canadian technology
IEW 2010 Biopolis, Singapore
Sample Talks (1)
Top 10 Mistakes to Avoid for Biotech Entrepreneurs
Find out the common mistakes biotech start-ups make and, more importantly, how to avoid them.
- Workshop Leader